Alpha blocker therapy for children with dysfunctional voiding and urinary retention

Mark P. Cain, Simon D. Wu, Paul F. Austin, C. D Anthony Herndon, Richard C. Rink

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: Alpha blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective alpha blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective α-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating alpha blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating alpha blocker therapy. Results: After starting doxazosin average PVR decreased to 8 ml (p

Original languageEnglish (US)
Pages (from-to)1514-1516
Number of pages3
JournalJournal of Urology
Volume170
Issue number4 II
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Urinary Retention
Doxazosin
Urinary Bladder
Therapeutics
Residual Volume
Adrenergic Antagonists
Antibiotic Prophylaxis
Cholinergic Antagonists
Urinary Incontinence
Urinary Tract Infections
Urine
Safety

Keywords

  • Adrenergic alpha-antagonists
  • Urinary incontinence
  • Urinary retention

ASJC Scopus subject areas

  • Urology

Cite this

Cain, M. P., Wu, S. D., Austin, P. F., Herndon, C. D. A., & Rink, R. C. (2003). Alpha blocker therapy for children with dysfunctional voiding and urinary retention. Journal of Urology, 170(4 II), 1514-1516. https://doi.org/10.1097/01.ju.0000085961.27403.4a

Alpha blocker therapy for children with dysfunctional voiding and urinary retention. / Cain, Mark P.; Wu, Simon D.; Austin, Paul F.; Herndon, C. D Anthony; Rink, Richard C.

In: Journal of Urology, Vol. 170, No. 4 II, 01.10.2003, p. 1514-1516.

Research output: Contribution to journalArticle

Cain, MP, Wu, SD, Austin, PF, Herndon, CDA & Rink, RC 2003, 'Alpha blocker therapy for children with dysfunctional voiding and urinary retention', Journal of Urology, vol. 170, no. 4 II, pp. 1514-1516. https://doi.org/10.1097/01.ju.0000085961.27403.4a
Cain, Mark P. ; Wu, Simon D. ; Austin, Paul F. ; Herndon, C. D Anthony ; Rink, Richard C. / Alpha blocker therapy for children with dysfunctional voiding and urinary retention. In: Journal of Urology. 2003 ; Vol. 170, No. 4 II. pp. 1514-1516.
@article{860608a779df4ba5931f0d0a1f110f1a,
title = "Alpha blocker therapy for children with dysfunctional voiding and urinary retention",
abstract = "Purpose: Alpha blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective alpha blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22{\%} of age expected capacity). All patients were treated with doxazosin, a selective α-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating alpha blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating alpha blocker therapy. Results: After starting doxazosin average PVR decreased to 8 ml (p",
keywords = "Adrenergic alpha-antagonists, Urinary incontinence, Urinary retention",
author = "Cain, {Mark P.} and Wu, {Simon D.} and Austin, {Paul F.} and Herndon, {C. D Anthony} and Rink, {Richard C.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1097/01.ju.0000085961.27403.4a",
language = "English (US)",
volume = "170",
pages = "1514--1516",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 II",

}

TY - JOUR

T1 - Alpha blocker therapy for children with dysfunctional voiding and urinary retention

AU - Cain, Mark P.

AU - Wu, Simon D.

AU - Austin, Paul F.

AU - Herndon, C. D Anthony

AU - Rink, Richard C.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: Alpha blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective alpha blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective α-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating alpha blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating alpha blocker therapy. Results: After starting doxazosin average PVR decreased to 8 ml (p

AB - Purpose: Alpha blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective alpha blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective α-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating alpha blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating alpha blocker therapy. Results: After starting doxazosin average PVR decreased to 8 ml (p

KW - Adrenergic alpha-antagonists

KW - Urinary incontinence

KW - Urinary retention

UR - http://www.scopus.com/inward/record.url?scp=0041315441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041315441&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000085961.27403.4a

DO - 10.1097/01.ju.0000085961.27403.4a

M3 - Article

C2 - 14501648

AN - SCOPUS:0041315441

VL - 170

SP - 1514

EP - 1516

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 II

ER -